Integrated Management of Post Remission Leukaemia to Optimise longevity and Enhance Quality of Life

  • Wei, Andrew (Primary Chief Investigator (PCI))
  • Fleming, Shaun Alan (Chief Investigator (CI))
  • Rady, Kirsty (Chief Investigator (CI))

Project: Research

Project Details

Project Description

Patients with acute leukaemia have a markedly higher risk of mortality than age matched controls. Half of younger patients with acute leukaemia will ultimately succumb to their disease or complications of therapy - a rate which is significantly higher in older adults with this disease.

The management of acute leukemia (AL) patients through intensive chemotherapy focuses on delivering sufficient chemotherapy, achieving and maintaining remission, minimising toxicity, and managing unavoidable complications. The toxicity of acute leukaemia therapy is well appreciated, and there is now increasing interest in understanding the impacts of therapy on health and quality of life post completion of intensive therapy.

Survivorship care is an important component in the continuum of cancer care. Important components of survivorship care include surveillance for disease recurrence, rehabilitation, monitoring and intervention for late effects of disease and treatment, health promotion, psychosocial support and evaluation of and intervention for socioeconomic consequences of disease and treatment.

Through a coordinated post-remission clinic for patients treated for acute leukaemia, we aim to systematically collect data to support optimal survivorship care, through the early detection of complications and patient needs to improve patient outcomes for acute leukaemias.

Through a combination of cross-sectional screening and longitudinal data collection, the project will collect data related to disease biology, health consequences of chemotherapy, familial cancer risk, patient reported outcomes of quality of life, physical and psychological wellbeing, and health status for clinical and economic evaluation.

This data will then be able to be widely utilised to optimise screening for complications of treatment and/or disease, provide early intervention where necessary and provide patient support services. This will work is relevant to all Clinical Haematology services to improve overall outcomes for patients with acute leukaemia.
Short titleIMPROVE
Effective start/end date14/03/1930/07/23